Re-Innovation in Clinical Trial Designs Based on Precision Therapy
September 2025
in “
Cancer Innovation
”

TLDR Clinical trials should use innovative designs and biomarkers to improve precision therapy and patient outcomes.
The article emphasizes the need for re-innovation in clinical trial designs to enhance precision therapy, criticizing traditional trials for their inefficiencies. It advocates for using biomarker technology and innovative designs like basket, umbrella, and platform trials to align therapies with patient characteristics in real-time. Examples such as the BFAST trial and FUTURE series demonstrate improved patient outcomes through targeted treatments. The document also highlights the use of MAMS designs for efficiency, as seen in the ROSSINI-2 trial, which reduced sample size while maintaining statistical power. Additionally, it explores the therapeutic potential of compounds like chlorogenic acid and honokiol, noting unexpected benefits such as hair growth. The integration of biomarkers and adaptive protocols is crucial for optimizing patient treatment and trial outcomes, underscoring the transformative potential of precision medicine.